Medical therapy for differentiated thyroid carcinoma.
While some of the studies with new therapeutic modalities are encouraging, all are in their early experimental phases. It is likely that better understanding of the molecular basis for differentiated thyroid carcinoma will lead to new therapy in the next decade.
Dulgeroff
A J
AJ
Division of Endocrinology and Metabolism W111D, West Los Angeles VA Medical Center, California 90073.
Hershman
J M
JM
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018265:Carcinoma, Papillary, Follicular / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D013964:Thyroid Neoplasms / Q000628:therapy*; D013974:Thyroxine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D013974:Thyroxine